NEWPORT NEWS, Va., July 16 Dilon Technologies, makers of agamma imaging system optimized for early breast cancer detection, todayannounced a three-year agreement with Amerinet, a leading national grouppurchasing organization. Effective immediately, the relationship offersAmerinet's 26,000 acute and non-acute healthcare providers and their patients'access to the Dilon 6800 Gamma Camera, used in detecting and diagnosing veryearly stage breast cancers.
"Dilon Technologies is committed to enhancing the standard of healthcarein communities across the nation, said David Rom, National Accounts Directorfor Dilon. "This strategic partnership with Amerinet will help physicians withdifficult-to-diagnose patients and continue to aid in the fight against breastcancer."
The Dilon 6800 performs a molecular breast imaging technique calledBreast-Specific Gamma Imaging (BSGI), which can detect lesions independent oftissue density and discover very early stage cancers. BSGI serves as acomplementary diagnostic adjunct procedure to mammography and ultrasound fordifficult-to-diagnose patients. With BSGI, the patient receives a radioactivetracing agent that is absorbed by all the cells in the body. Cancerous cellsin the breast, due to their increased rate of metabolic activity, absorb agreater amount of the tracing agent than normal healthy cells, and generallyappear as "hot spots" on the BSGI image.
Amerinet strategically partners with healthcare providers to reduce costsand improve the delivery of quality care. Supported by a team of clinical,data and supply chain experts, Amerinet offers a suite of tools, programs andservices including a comprehensive and competitive portfolio that deliverspractical solutions to address members' specific needs. To learn more, visithttp://www.amerinet-gpo.com.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical imaging products tomarket. Dilon's cornerstone product, the Dilon 6800, is a high-resolution,small field-of-view gamma camera, optimized to perform Breast-Specific GammaImaging (BSGI), a molecular breast imaging procedure which images themetabolic activity of breast lesions through radiotracer uptake. Many leadingmedical centers around the country are now offering BSGI to their patients,including: Cornell University Medical Center, New York; George WashingtonUniversity Medical Center, Washington, D.C.; and The Rose, Houston. For moreinformation on Dilon Technologies please visit http://www.dilon.com.
SOURCE Dilon Technologies